BIOGEN INC. Accumulated Other Comprehensive Income
BIOGEN INC. (BIIB) had Accumulated Other Comprehensive Income of -$140.20 million as of 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-04-29
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$140.20M.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$182.00M.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$214.80M.
- 2025-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$238.10M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax | Accumulated Other Comprehensive Income (Loss), Net of Tax as first filed |
|---|---|---|
| 2026-03-31 | -$140.20M 10-Q · filed 2026-04-29 | |
| 2025-12-31 | -$182.00M 10-Q · filed 2026-04-29 | |
| 2025-09-30 | -$214.80M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | -$238.10M 10-Q · filed 2025-07-31 | |
| 2025-03-31 | -$174.50M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | -$136.20M 10-K · filed 2026-02-06 | |
| 2024-09-30 | -$145.70M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | -$146.00M 10-Q · filed 2024-10-30 | |
| 2024-03-31 | -$160.50M 10-Q · filed 2024-08-01 | |
| 2023-12-31 | -$153.70M 10-K · filed 2025-02-12 | |
| 2023-09-30 | -$159.30M 10-Q · filed 2024-10-30 | |
| 2023-06-30 | -$172.80M 10-Q · filed 2024-10-30 | |
| 2023-03-31 | -$172.00M 10-Q · filed 2024-08-01 | |
| 2022-12-31 | -$164.90M 10-Q · filed 2024-10-30 | |
| 2022-09-30 | -$163.60M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | -$110.40M 10-Q · filed 2023-07-25 | |
| 2022-03-31 | -$115.20M 10-Q · filed 2023-04-25 | |
| 2021-12-31 | -$106.70M 10-Q · filed 2023-11-08 | |
| 2021-09-30 | -$136.60M 10-Q · filed 2022-10-25 | |
| 2021-06-30 | -$171.80M 10-Q · filed 2022-07-20 | |
| 2021-03-31 | -$174.30M 10-Q · filed 2022-05-03 | |
| 2020-12-31 | -$299.00M 10-Q · filed 2022-10-25 | |
| 2020-09-30 | -$225.50M 10-Q · filed 2021-10-20 | |
| 2020-06-30 | -$181.00M 10-Q · filed 2021-07-22 | |
| 2020-03-31 | -$149.30M 10-Q · filed 2021-04-22 | |
| 2019-12-31 | -$135.20M 10-Q · filed 2021-10-20 | |
| 2019-09-30 | -$92.30M 10-Q · filed 2020-10-21 | |
| 2019-06-30 | -$252.90M 10-Q · filed 2020-07-22 | |
| 2019-03-31 | -$219.80M 10-Q · filed 2020-04-23 | |
| 2018-12-31 | -$240.40M 10-Q · filed 2020-10-21 | |
| 2018-09-30 | -$248.30M 10-Q · filed 2019-10-22 | |
| 2018-06-30 | -$261.60M 10-Q · filed 2019-07-24 | |
| 2018-03-31 | -$303.90M 10-Q · filed 2019-04-24 | |
| 2018-01-01 | -$316.90M 10-K · filed 2020-02-06 | |
| 2017-12-31 | -$318.40M 10-K · filed 2020-02-06 | |
| 2017-09-30 | -$329.40M 10-Q · filed 2018-10-23 | |
| 2017-06-30 | -$338.80M 10-Q · filed 2018-07-24 | |
| 2017-03-31 | -$325.20M 10-Q · filed 2018-04-24 | |
| 2016-12-31 | -$319.90M 10-K · filed 2020-02-06 | |
| 2016-09-30 | -$300.90M 10-Q · filed 2017-10-24 | |
| 2016-06-30 | -$282.80M 10-Q · filed 2017-07-25 | |
| 2016-03-31 | -$259.30M 10-Q · filed 2017-04-25 | |
| 2015-12-31 | -$224.00M 10-K · filed 2019-02-06 | |
| 2015-09-30 | -$157.40M 10-Q · filed 2016-10-26 | -$157.42M 10-Q · filed 2015-10-21 |
| 2015-06-30 | -$101.00M 10-Q · filed 2016-07-21 | -$101.03M 10-Q · filed 2015-07-24 |
| 2015-03-31 | -$70.50M 10-Q · filed 2016-04-21 | -$70.54M 10-Q · filed 2015-04-24 |
| 2014-12-31 | -$59.50M 10-K · filed 2018-02-01 | -$59.49M 10-K · filed 2015-02-04 |
| 2014-09-30 | -$38.00M 10-Q · filed 2015-10-21 | -$37.99M 10-Q · filed 2014-10-22 |
| 2014-06-30 | -$26.70M 10-Q · filed 2015-07-24 | -$26.68M 10-Q · filed 2014-07-23 |
| 2014-03-31 | -$22.40M 10-Q · filed 2015-04-24 | -$22.36M 10-Q · filed 2014-04-23 |
| 2013-12-31 | -$27.70M 10-K · filed 2017-02-02 | -$27.75M 10-K · filed 2014-02-06 |
| 2013-09-30 | -$29.30M 10-Q · filed 2014-10-22 | -$29.32M 10-Q · filed 2013-10-28 |
| 2013-06-30 | -$55.10M 10-Q · filed 2014-07-23 | -$55.14M 10-Q · filed 2013-07-25 |
| 2013-03-31 | -$68.00M 10-Q · filed 2014-04-23 | -$67.97M 10-Q · filed 2013-04-25 |
| 2012-12-31 | -$55.30M 10-K · filed 2016-02-03 | -$55.30M 10-K · filed 2013-02-05 |
| 2012-09-30 | -$51.12M 10-Q · filed 2012-10-25 | |
| 2012-06-30 | -$50.56M 10-Q · filed 2012-07-24 | |
| 2012-03-31 | -$17.71M 10-Q · filed 2012-05-01 | |
| 2011-12-31 | -$26.50M 10-K · filed 2015-02-04 | -$26.54M 10-K · filed 2012-02-03 |
| 2011-09-30 | $7.57M 10-Q · filed 2011-10-28 | |
| 2011-06-30 | $25.71M 10-Q · filed 2011-07-26 | |
| 2011-03-31 | -$992.00K 10-Q · filed 2011-04-21 | |
| 2010-12-31 | -$21.60M 10-K · filed 2014-02-06 | -$21.61M 10-K · filed 2011-02-04 |
| 2010-09-30 | -$9.16M 10-Q · filed 2010-10-26 | |
| 2010-06-30 | -$28.42M 10-Q · filed 2010-07-20 | |
| 2010-03-31 | $22.87M 10-Q · filed 2010-04-20 | |
| 2009-12-31 | $50.50M 10-K · filed 2011-02-04 | |
| 2009-09-30 | $37.11M 10-Q · filed 2009-10-21 | |
| 2009-06-30 | $11.29M 10-Q · filed 2009-07-17 | |
| 2008-12-31 | -$11.11M 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |